Paola Lopez-Marte

Dr. Paola Lopez-Marte


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2024 in Viruses
Verified
Journal Article
Open access
PDF file
AEAna M Espino
Ana M Espino
AAAlbersy Armina-Rodriguez
Albersy Armina-Rodriguez
LALaura Alvarez
Laura Alvarez
COCarlimar Ocasio-Malavé
Carlimar Ocasio-Malavé
RRRiseilly Ramos-Nieves
Riseilly Ramos-Nieves
CSCarlos A. Sariol
Carlos A. Sariol
The aim of this study was to analyze the profiles of IgG subclasses in COVID-19 convalescent Puerto Rican subjects and compare these profiles with those of non-infected immunocompetent or immunocompromised subjects that received two or more doses of an mRNA vaccine. The most notable findings from this study are as follows: (1) Convalescent subjects that were not hospitalized developed high and long-lasting antibody responses. (2) Both IgG1 and IgG3 subclasses were more prevalent in the SARS-CoV-2-infected population, whereas IgG1 was more prevalent after vaccination. (3) Individuals that were infected and then later received two doses of an mRNA vaccine exhibited a more robust neutralizing capacity against Omicron than those that were never infected and received two doses of an mRNA vaccine. (4) A class switch toward the “anti-inflammatory” antibody isotype IgG4 was induced a few weeks after the third dose, which peaked abruptly and remained at high levels for a long period. Moreover, the high levels of IgG4 were concurrent with high neutralizing percentages against various VOCs including Omicron. (5) Subjects with IBD also produced IgG4 antibodies after the third dose, although these antibody levels had a limited effect on the neutralizing capacity. Knowing that the mRNA vaccines do not prevent infections, the Omicron subvariants have been shown to be less pathogenic, and IgG4 levels have been associated with immunotolerance and numerous negative effects, the recommendations for the successive administration of booster vaccinations to people should be revised.

10 January 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
AEAna M Espino
Ana M Espino
AAAlbersy Armina-Rodriguez
Albersy Armina-Rodriguez
LALaura Alvarez
Laura Alvarez
COCarlimar Ocasio-Malavé
Carlimar Ocasio-Malavé
RRRiseilly Ramos-Nieves
Riseilly Ramos-Nieves
CSCarlos A. Sariol
Carlos A. Sariol
The aim of this study was to analyze the profile of IgG subclasses in COVID-19 convalescent Puerto Rican subjects and compare this profile with those exhibited by no-infected immunocompetent or immunocompromised subjects that received the mRNA vaccine. The most notable find-ngs from this study are: 1) Convalescent subjects that were not hospitalized developed high and long-lasting antibody response. 2) Both, IgG1 and IgG3 are the subclasses more prevalent in the SARS-CoV-2 infected population whereas IgG1 is more prevalent after vaccination. 3) Individuals that first had the infection and further received two doses of mRNA vaccines exhibited more robust neutralizing capacity against Omicron than those that were never infected and received two doses of Pfizer-BioNTech vaccine. 4) A class switch toward the “anti-inflammatory” anti-body isotype IgG4 is induced a few weeks after the third dose, which peaked abruptly and remained at high levels for a long period. Moreover, the high levels of IgG4 are concurrent with high neutralizing percentages against various VOC including Omicron. 5) Subjects with IBD also develop IgG4 after the third dose, although these antibody levels have limited effect on the neutralizing capacity. Knowing that the mRNA vaccines do not prevent reinfections, all Omicron sub-variants that are dominant worldwide have shown to be less pathogenic, and the IgG4 levels have been associated to immunotolerance and causative of numerous negative effects, the recommendations of successive administration of booster vaccinations to people should be revised.

11 August 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
PLPaola Lopez-Marte
Paola Lopez-Marte
ASAlondra Soto-González
Alondra Soto-González
LTLizzie Marie Ramos Tollinchi
Lizzie Marie Ramos Tollinchi
STStephan J Torres
Stephan J Torres
MFMariana Ferre
Mariana Ferre
CSCarlos A. Sariol
Carlos A. Sariol
Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine’s effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the third vaccine dose can neutralize SARS-CoV-2 variants in this population remains unknown. This study aims to evaluate the humoral response of SARS-CoV-2 variants in patients with IBD 60 days after the third vaccine dose [BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)]. Fifty-six subjects with IBD and 12 healthy subjects were recruited. Ninety percent of patients with IBD (49/56) received biologics and/or immunomodulatory therapy. Twenty-four subjects with IBD did not develop effective neutralizing capability against the Omicron variant. Seventy percent (17/24) of those subjects received anti-tumor necrosis factor therapy [10 = adalimumab, 7 = infliximab], two of which had a history of COVID-19 infection, and one subject did not develop immune neutralization against three other variants: Gamma, Epsilon, and Kappa. All subjects in the control group developed detectable antibodies and effective neutralization against all seven SARS-CoV-2 variants. Our study shows that patients with IBD might not be protected against SARS-CoV-2 variants, and more extensive studies are needed to evaluate optimal immunity.

1 January 2023 in ACG Case Reports Journal
Verified
Journal Article
Open access
PLPaola Lopez-Marte
Paola Lopez-Marte
FAFray Arroyo-Mercado
Fray Arroyo-Mercado
AAAamer Abbass
Aamer Abbass
AMAntonio Mendoza-Ladd
Antonio Mendoza-Ladd
Hemorrhagic cholecystitis is a rare entity with few cases reported in the literature. We report a case of a 42-year-old man with cirrhosis who presented to the hospital with abdominal pain in the right upper quadrant radiating to the back. Computed tomography scan showed findings consistent with acute cholecystitis. Owing to decompensated cirrhosis, he was not a good candidate for cholecystectomy. Endoscopic ultrasound-guided cholecystoenterostomy was performed that immediately yielded a large amount of old blood with clots along with some bile consistent with acute hemorrhagic cholecystitis. After the drainage, he had an uneventful hospitalization.

1 September 2024
Verified
Journal Article
Closed access
PLPaola Lopez-Marte
Paola Lopez-Marte
BGBianca Goyco-Cortes
Bianca Goyco-Cortes
BRBarbara Rosado-Carrion
Barbara Rosado-Carrion